Canadian scientists to get major grant from Movember Foundation

According to media reports, the Movember Foundation has just awarded $4.7 million to “a team of Canadian scientists” to support the development of molecular diagnostic tests that could be used to guide the treatment of prostate cancer. … READ MORE …

Quality of life after standard therapies for localized prostate cancer

Assessment of patient quality of life (QoL) after standard forms of treatment for localized prostate cancer is difficult for many reasons — not least because there is no real agreement among members of the research community about the best ways to measure QoL or patient satisfaction after treatment. … READ MORE …

IGF1 and risk for prostate cancer among African Americans

There have been suggestions that genetic variations in subtypes of insulin-like growth factor 1 (IGF1) might be responsible for at least some of the increase in risk for prostate cancer among African Americans and others of historic African ethnicity such as Afro-Caribbeans. … READ MORE …

Is baseline free serum T a factor in appropriate management on active surveillance?

Analysis of data from a cohort of 154 Chilean men with prostate cancer, all being monitored on active surveillance, suggests that free serum testosterone levels (but not total testosterone levels) may be able to help to predict which of these men will go on to need active treatment. … READ MORE …

ART or SRT in high-risk patients post-surgery?

As many of our regular readers will know, there is no clear answer to the question whether, among men at elevated risk of progressive disease after first-line surgery, it is better to have adjuvant radiation therapy (ART) within a few months of surgery or to wait until salvage radiation therapy (SRT) is clearly advisable. … READ MORE …

The absolute increase in risk of prostate cancer after a vasectomy

Late last week we commented briefly on a paper by Siddiqui et al. that had assessed the association between risk for a diagnosis of prostate cancer and the prior occurrence of a vasectomy in men who participated in the Health Professionals Follow-up Study (HPFS). … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,113 other followers